Alimera Science: (NASD: ALIM)
$4.42
0.04 (0.91%)
Volume 70,344
May 21 04:00 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 4.22 - 4.45 |
| 52wk Low - High | 1.26 - 5.10 |
| Previous Close | 4.38 |
| Avg. Volume | 139,888 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 139.35 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.68 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
96 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.86 |
| Expected Earnings Growth | NA |
Company Description
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AETERNA ZENTARS | AEZS | 2.08 | |
|
| ANIKA THERAPEUT | ANIK | 14.45 | |
|
| GENTIUM SPA-ADR | GENT | 8.90 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.75 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.45 | |
|
| ALEXION PHARMA | ALXN | 102.67 | |
|
| ALKERMES INC | ALKS | 31.98 | |
|
| ALNYLAM PHARMA | ALNY | 28.03 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.86 |
| Sales | NA |
| Net Income | -29 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
pSivida announces availability of diabetic macular edema drug in Germany - Datamonitor
May 21, 2013
Alimera Sciences announces availability of DME drug in Germany - Datamonitor
May 20, 2013
pSivida Reports Third Quarter Fiscal Year 2013 Results - Close-Up Media
May 16, 2013
Alimera Sciences Inc is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com - Newsfile Corp
May 15, 2013
Market Maker Surveillance Report. ESI, FMCC, LOTE, UNTK, ALIM, FNMA, Winning Stocks With Lowest Price Friction For Tuesday, May 14th 2013 - M2
May 15, 2013
Monday Sector Leaders: Biotechnology, Drugs - Marketnewsvideo.Com
May 13, 2013
WEALTHMAKERS.COM Issues Bullish Research Reports on ALIM, CACB, CHI, CYCCP, DL, EMR - M2
May 13, 2013
pSivida Corp. Reports Commercial Launch of ILUVIEN in Germany, 1st Patient Treated - Close-Up Media
May 12, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 1 |
| Average Target Price | NA |
| Industry Rank by ABR | 96 out of 265 |
| Rank in Industry | NA |
